Premaitha Licenses NIPT Tech From Illumina Under Settlement

Sep 19, 2018

|

NEW YORK (GenomeWeb) – Premaitha Health said today that it has settled its patent dispute and signed a licensing and supply agreement with Illumina related to noninvasive prenatal testing technology.

Under the agreement, Manchester, UK-based Premaitha has licensed Illumina's NIPT patent pool, allowing it to offer testing in Europe and other countries covered by the intellectual property.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Teasing Out How Infections Spread

The Chan Zuckerberg Biohub is working with California's health department to sequence viral samples from COVID-19 patients to trace viral introductions, according to the San Francisco Chronicle.

How Far the Butterfly Flies

Despite differences in their migration habits, eastern and western monarch butterflies are genetically similar, according to a study in Molecular Ecology.

Fast COVID-19 Testing for UK

The UK is implementing COVID-19 testing with a 90-minute turnaround time.

PLOS Papers on Mycetoma Molecular Epidemiology, Campylobacter in Retail Meat, More

In PLOS this week: identification of fungal species in subcutaneous infections, sequencing of Campylobacter found in raw meat from retail stores, and more.

Featured White Papers

GX Solutions – Noise Reduction

GX Solutions: The First Professional Medical-Grade Refrigerators

NGS-Based Target Capture for SARS-CoV-2 Detection and Characterization

Seeing Beyond the Limit: Detect Residual Disease and Assess Treatment Response

Aug

18

Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug

24

Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug

25

Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Aug

27

Featured Webinar

CRISPR/Cas9 Screens to Investigate Mechanisms of Cancer Drug Resistance

Over 70 percent of breast cancers are estrogen receptor positive and are treated with endocrine therapy.

Menu

Premaitha Licenses NIPT Tech From Illumina Under Settlement

To read the full story....

Breaking News

Pacific Biosciences Q2 Revenues Drop 14 Percent

Bruker Posts 13 Percent Decline in Q2 Revenues

US Appeals Court Lifts Injunction on 10x Genomics' Linked-Reads, Single-Cell CNV Assays

Cervical Cancer Study in Ugandan Women Finds HPV-Specific Tumor DNA Methylation, Gene Expression

Stupid Strong Awards City of Hope $125K for Gastric Cancer Liquid Biopsy Research

Metabolon, Merck KGaA Form Metabolomics Alliance

The Scan

Teasing Out How Infections Spread

How Far the Butterfly Flies

Fast COVID-19 Testing for UK

PLOS Papers on Mycetoma Molecular Epidemiology, Campylobacter in Retail Meat, More

Featured White Papers

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

Utility of Novel RNA-Based Tools in Oncology Drug Development

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

CRISPR/Cas9 Screens to Investigate Mechanisms of Cancer Drug Resistance

What's Popular?

NIH Awards $249M to Seven Firms for Rapid Acceleration of COVID-19 Diagnostics

Exact Sciences Positions Itself as Cancer Testing Provider of Future as COVID Crisis Continues

Pacific Biosciences, Asuragen Collaborate on Clinical Assays

NHS Will Roll Out COVID-19 Tests From DnaNudge, Oxford Nanopore Across UK

SARS-CoV-2 E Gene SNP Raises Concerns About Test Accuracy, Transparency

Sponsorships